Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lymphomas

Clinical Trial at: Arizona Oncology - Glendale

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

7200 W Bell Road, Building A
Glendale, Arizona 85308
P: (623) 487-4822

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Scottsdale

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

10460 N 92nd St, Suite 402
Scottsdale, Arizona 85258
P: (480) 860-2540

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Scottsdale

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

10197 N 92nd St, Suite 101
Scottsdale, Arizona 85258
P: (480) 993-2950

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Sedona

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Tucson

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Phoenix

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Tucson

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Arizona Oncology - Sedona

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Sedona

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Arizona Oncology - Sedona

A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

  • Details

ClinicalTrials.gov ID: NCT02872714
Diagnosis Type: NA
USOR Number: 15228

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Arizona Oncology - Sedona

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Sedona

A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)

  • Details

ClinicalTrials.gov ID: NCT02872714
Diagnosis Type: NA
USOR Number: 15228

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Lung Cancer

Clinical Trial at: Arizona Oncology - Sedona

CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

  • Details

ClinicalTrials.gov ID: NCT02869789
Diagnosis Type: NSCLC
USOR Number: 16156

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Lung Cancer

Clinical Trial at: Arizona Oncology - Sedona

Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

  • Details

ClinicalTrials.gov ID: NCT02998528
Diagnosis Type: NSCLC
USOR Number: 16161

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Arizona Oncology - Sedona

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

  • Details

ClinicalTrials.gov ID: NCT02952534
Diagnosis Type: NA
USOR Number: 16237

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Arizona Oncology - Sedona

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

3700 W State Route 89A
Sedona, Arizona 86336
P: (928) 204-4163

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

  • Details

ClinicalTrials.gov ID: NCT03661320
Diagnosis Type: NA
USOR Number: 18095

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

  • Details

ClinicalTrials.gov ID: NCT03661320
Diagnosis Type: NA
USOR Number: 18095

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

  • Details

ClinicalTrials.gov ID: NCT03661320
Diagnosis Type: NA
USOR Number: 18095

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Fallopian Tube Cancer

Clinical Trial at: Arizona Oncology - Scottsdale

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  • Details

ClinicalTrials.gov ID: NCT03522246
Diagnosis Type: NA
USOR Number: 17182

  • Practice Details

10197 N 92nd St, Suite 101
Scottsdale, Arizona 85258
P: (480) 993-2950

More Details View Practice Page

Pages